Acme United (NYSE:ACU) Given New $70.00 Price Target at Freedom Broker

Key Points

• Freedom Broker raised Acme United’s price target to $70 from $58 while maintaining a “hold” rating, implying approximately 4.7% upside from the reported $66.85 share price.
• Acme United shares were trading near their 52-week high, with a market capitalization of about $254.7 million and a price-to-earnings ratio of 13.67. The stock has risen significantly above its 200-day moving average of $49.96.
• Insiders sold 26,063 shares worth roughly $1.53 million over the past three months, while institutional investors own 62.1% of the company. Recent business updates cited strong quarterly sales and earnings growth, though a tariff refund raised questions about the sustainability of the earnings beat.

Acme United (NYSE:ACU - Get Free Report) had its target price raised by analysts at Freedom Broker from $58.00 to $70.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a "hold" rating on the stock. Freedom Broker's price target would indicate a potential upside of 4.71% from the stock's current price.

Acme United Stock Performance

Acme United stock traded up $1.07 during midday trading on Wednesday, reaching $66.85. 34,014 shares of the stock traded hands, compared to its average volume of 24,458. The company has a current ratio of 4.41, a quick ratio of 1.91 and a debt-to-equity ratio of 0.30. The firm has a fifty day moving average price of $62.50 and a two-hundred day moving average price of $49.96. The firm has a market cap of $254.70 million, a price-to-earnings ratio of 13.67 and a beta of 0.40. Acme United has a fifty-two week low of $35.50 and a fifty-two week high of $67.32.

Insider Activity at Acme United

In other news, COO Brian Olschan sold 7,308 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $61.48, for a total value of $449,295.84. Following the completion of the transaction, the chief operating officer owned 41,172 shares of the company's stock, valued at approximately $2,531,254.56. This represents a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Brian Barker sold 3,821 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $60.50, for a total value of $231,170.50. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 26,063 shares of company stock worth $1,526,133 in the last three months. 29.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Acme United

Institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new position in Acme United during the 2nd quarter valued at about $28,000. Deutsche Bank AG bought a new stake in shares of Acme United during the 2nd quarter worth about $162,000. James Investment Research Inc. acquired a new stake in shares of Acme United in the 1st quarter worth approximately $217,000. Empowered Funds LLC acquired a new stake in shares of Acme United in the 1st quarter worth approximately $234,000. Finally, Simplicity Wealth LLC acquired a new stake in shares of Acme United in the 3rd quarter worth approximately $371,000. Institutional investors and hedge funds own 62.10% of the company's stock.

Key Acme United News

Here are the key news stories impacting Acme United this week:

• Positive Sentiment: Strong quarterly growth and earnings beat: Third-quarter net sales rose 18% year over year to $58.0 million, while comparable sales excluding the My Medic acquisition increased 10%. Earnings of $0.80 per share exceeded the $0.71 consensus estimate, supporting the positive market reaction. Acme United Reports Third Quarter 2026 Net Sales Increase of 18%
• Positive Sentiment: Cost savings ahead: Acme United plans to close its DMT/Marlborough facility, a move expected to generate more than $1 million in annual savings beginning in January 2027. The savings could provide additional support for margins and future profitability. Acme United outlines DMT plant closure and annual savings
• Positive Sentiment: Business momentum remains constructive: Nine-month sales increased 16% to $173.0 million, or 8% on a comparable basis excluding My Medic. Management commentary and investor coverage indicate that the underlying operating performance is expected to remain solid. Acme United three key takeaways for long-term investors
• Neutral Sentiment: Acquisition contributed to growth: The My Medic acquisition helped lift reported sales, while comparable growth was more moderate. Investors will likely focus on whether the company can sustain organic growth and integrate the acquired business. Acme United Q3 earnings ride tariff refund boost
• Negative Sentiment: Quality of the earnings beat is a concern: Coverage highlighted that a tariff refund boosted third-quarter results, raising questions about how much of the earnings upside is recurring. One analyst viewed the operating performance favorably but said the current valuation was not attractive enough to chase the stock. Acme United Q3 performance and valuation analysis

Acme United Company Profile

Acme United Corporation is a manufacturer and supplier of first aid and medical products, cutting instruments, measuring tools and school and office supplies. The company serves the consumer, industrial, medical, school and office markets through a portfolio of branded and private-label products.

Its product offerings include workplace first aid cabinets and kits, medical and emergency supplies, scissors, shears, knives, sharpeners, rulers and other measuring instruments. Acme United markets products under brands such as PhysiciansCare, First Aid Only, Pac-Kit, Westcott and Clauss.

Founded in 1867, Acme United is headquartered in Fairfield, Connecticut, and serves customers in the United States, Canada and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.